Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Q4 prepare to be amazed

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Feb 22, 2022 12:51pm

196 Views

Post# 34450712

RE:RE:RE:Q4 prepare to be amazed

Get all your questions ready and teed up to submit. I believe you need to be on the web presentation version to be able to submit questions and it can't be done via phone call in.

palinc2000 wrote:
I was hoping for a PR with material news on Nash and or Phase 1 before the release of 4th Quarter results.... I dont expect any phase 1 data or partnersip agreement to be released on Thursday ... other than more precise timeline on when we can expect news
I would hope that they will provide some sales guidance and maybe add more color on shareholder friendly funds raise

SPCEO1 wrote: Given that TH just announced bringing the sales force in house, I would not bet a lot on better than expected sales. I don't, however, expect sales to be awful in Q4 based on the always suspect Bloomberg sales estimates. A NASH partnership is a possibility but I am not sure it is a strong possibility at this time. I also think if they have one lined up, they might want to announce that separately from from the Q4 press release. Hopefully we will at least get a substantive update on the phase 1a. Since they are changing over to a new sales force, I doubt they will be willing to give any guidance on Q2 or all of 2022 yet. There is bound to be a blip in sales as they transition to the new sales approach.

Really, the key issue is the phase 1a situation. Everything really hinges on that trial producing intriguing results. If the phase 1a has promising results, we have a lot to look forward to. Everything else is mostly noise at this point.

Biobob wrote: Better than expected sales, Nash Partnership, P1a data surprise (a good one of course), guidance... Covid won't be an excuse from now on... Paul it's time to deliver share appreciation, it's the purpose of our investment and it is time you justify the expense.